Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 10/20 | 0.49 |
| ▸ | OGA | O60502 | 1/20 | 0.41 |
| ▸ | PYGL | P06737 | 3/20 | 0.41 |
| ▸ | PYGM | P11217 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1674154 | 1.00 | PYGB (0.49) | PYGBOGAPYGLPYGMTSHR | |
| SCHEMBL28379664 | 1.00 | PYGB (0.49) | PYGBOGAPYGLPYGMTSHR | |
| SCHEMBL15284881 | 1.00 | PYGB (0.49) | PYGBOGAPYGLPYGMTSHR | |
| SCHEMBL29406981 | 1.00 | PYGB (0.49) | PYGBOGAPYGLPYGMTSHR | |
| SCHEMBL31598843 | 0.83 | PYGB (0.43) | PYGBOGAPYGLPYGMTSHR | |
| SCHEMBL30569120 | 0.83 | PYGB (0.43) | PYGBOGAPYGLPYGMTSHR | |
| SCHEMBL11505360 | 0.83 | PYGB (0.52) | PYGBPYGLPYGM | |
| SCHEMBL9221292 | 0.81 | PYGB (0.48) | PYGBOGAPYGLPYGMTSHR | |
| SCHEMBL10357870 | 0.81 | PYGB (0.51) | PYGBOGAPYGLPYGMTSHR | |
| SCHEMBL30381206 | 0.80 | PYGB (0.43) | PYGBPYGLPYGMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186599-A1 | BLOCK COPOLYMERS | GENEVANT SCIENCES GMBH (CH) | 2025-06-12 | — | — | US | claimed |
| WO-2024196898-A1 | CHEMICALLY MODIFIED NONCODING NUCLEOTIDES | CAMFORD LABS INC. (US) | 2024-09-26 | — | — | WO | claimed |
| US-20260146252-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | IONIS PHARMACEUTICALS, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| EP-4748381-A2 | PRODUCTS AND COMPOSITIONS | Silence Therapeutics GmbH (DE) | 2026-05-27 | — | — | EP | disclosed |
| EP-4748382-A2 | PRODUCTS AND COMPOSITIONS | Silence Therapeutics GmbH (DE) | 2026-05-27 | — | — | EP | disclosed |
| EP-4534092-B1 | COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION | IONIS PHARMACEUTICALS INC (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4717773-A2 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF A TARGET GENE COMPRISING PHOSPHORODITHIOATE LINKAGES | Silence Therapeutics GmbH (DE) | 2026-04-01 | — | — | EP | disclosed |
| EP-4711459-A2 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | Ionis Pharmaceuticals, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-3710585-B1 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF A TARGET GENE COMPRISING PHOSPHORODITHIOATE LINKAGES | SILENCE THERAPEUTICS GMBH (DE) | 2026-02-25 | — | — | EP | disclosed |
| US-20260049314-A1 | ANTISENSE OLIGONUCLEOTIDE-BASED ANTI-FIBROTIC THERAPEUTICS | UNIVERSITY OF ROCHESTER (US) | 2026-02-19 | — | — | US | disclosed |
| US-20260035695-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | IONIS PHARMACEUTICALS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20220153775-A1 | COMPOUNDS AND METHODS FOR MODULATING ANGIOTENSINOGEN EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| EP-3986929-A1 | ASSESSMENT OF DISEASE RISK FACTORS IN CORRELATION WITH NEU5GC INGESTED IN FOOD | Ramot at Tel-Aviv University Ltd. (IL) | 2022-04-27 | — | — | EP | disclosed |
| US-11312964-B2 | Compositions and methods for modulating growth hormone receptor expression | IONIS PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-11312962-B2 | Modulators of diacyglycerol acyltransferase 2 (DGAT2) | IONIS PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| EP-3320094-B1 | MODULATORS OF DIACYGLYCEROL ACYLTRANSFERASE 2 (DGAT2) | IONIS PHARMACEUTICALS INC (US) | 2022-04-13 | — | — | EP | disclosed |
| US-11299736-B1 | Conjugated antisense compounds and their use | IONIS PHARMACEUTICALS, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| EP-3974534-A1 | COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2022-03-30 | — | — | EP | disclosed |
| US-20220090067-A1 | PRODUCTS AND COMPOSITIONS | SILENCE THERAPEUTICS GMBH (DE) | 2022-03-24 | — | — | US | disclosed |
| EP-3960183-A1 | COMPOUNDS AND METHODS FOR MODULATING ANGIOTENSINOGEN EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2022-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260146252-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | SI, FABP2, FUT6 | PYGB 677/4885OGA 16/4885PYGL 135/4885 |
| US-20260035695-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | APOL1, APOB, PCSK9 | PYGB 918/4885OGA 69/4885PYGL 443/4885 |
| US-20250186599-A1 | BLOCK COPOLYMERS | CHMP4B, CD47, EEA1 | PYGB 1109/4885OGA 3083/4885PYGL 2035/4885 |
| US-20260049314-A1 | ANTISENSE OLIGONUCLEOTIDE-BASED ANTI-FIBROTIC THERAPEUTICS | UPF1, HNRNPF, RNMT | PYGB 4304/4885OGA 622/4885PYGL 2335/4885 |
| US-11299736-B1 | Conjugated antisense compounds and their use | CSGALNACT1, GALNT1, GALNT6 | PYGB 696/4885OGA 10/4885PYGL 615/4885 |
| US-11312962-B2 | Modulators of diacyglycerol acyltransferase 2 (DGAT2) | DGAT2, DGAT1, PLAAT2 | PYGB 492/4885OGA 623/4885PYGL 845/4885 |
| US-20220153775-A1 | COMPOUNDS AND METHODS FOR MODULATING ANGIOTENSINOGEN EXPRESSION | AGT, AGTR1, AGTR2 | PYGB 1542/4885OGA 263/4885PYGL 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.